Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 956082, 12 pages
http://dx.doi.org/10.1155/2015/956082
Research Article

Serum Levels of IL-1β, IL-6, TGF-β, and MMP-9 in Patients Undergoing Carotid Artery Stenting and Regulation of MMP-9 in a New In Vitro Model of THP-1 Cells Activated by Stenting

1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2Department of Neurology, The Fifth People’s Hospital of Chongqing, Chongqing 400062, China
3Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, USA
4Department of Neurology, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China

Received 9 March 2015; Revised 7 May 2015; Accepted 12 May 2015

Academic Editor: Stefanie B. Flohé

Copyright © 2015 Rongrong Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. K. Lovett, A. J. Coull, and P. M. Rothwell, “Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies,” Neurology, vol. 62, no. 4, pp. 569–573, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Wasser, S. Schnaudigel, J. Wohlfahrt, M.-N. Psychogios, M. Knauth, and K. Gröschel, “Inflammation and in-stent restenosis: the role of serum markers and stent characteristics in carotid artery stenting,” PLoS ONE, vol. 6, no. 7, Article ID e22683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Inoue, K. Croce, T. Morooka, M. Sakuma, K. Node, and D. I. Simon, “Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis,” JACC: Cardiovascular Interventions, vol. 4, no. 10, pp. 1057–1066, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. N. Khouzam, M. Shaheen, R. K. Aziz, and U. N. Ibebuogu, “The important role of inflammatory biomarkers pre and post bare-metal and drug-eluting stent implantation,” Canadian Journal of Cardiology, vol. 28, no. 6, pp. 700–705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. F. G. P. Welt and C. Rogers, “Inflammation and restenosis in the stent era,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 11, pp. 1769–1776, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. G. T. Jones, G. P. Tarr, L. V. Phillips, G. T. Wilkins, A. M. van Rij, and M. J. A. Williams, “Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis,” Atherosclerosis, vol. 207, no. 2, pp. 603–607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Liu, Y. Liu, H. Jiang et al., “Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention,” Inflammation, vol. 36, no. 5, pp. 1129–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. M. Katsaros, S. P. Kastl, G. Zorn et al., “Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9,” JACC: Cardiovascular Interventions, vol. 3, no. 1, pp. 90–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. G. T. Jones, I. P. Kay, J. W. S. Chu et al., “Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. e121–e125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Sardella, P. Mariani, M. D'Alessandro et al., “Early elevation of interleukin-1β and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina,” Thrombosis Research, vol. 117, no. 6, pp. 659–664, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Joner, A. Farb, Q. Cheng et al., “Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-β and MCP-1,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 182–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Q. Chen, M. Jin, F. Yang, J. Zhu, Q. Xiao, and L. Zhang, “Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling,” Mediators of Inflammation, vol. 2013, Article ID 928315, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Zalba, A. Fortuño, J. Orbe et al., “Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 587–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. J. Feldman, M. Mazighi, A. Scheuble et al., “Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit,” Circulation, vol. 103, no. 25, pp. 3117–3122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. F. G. P. Welt, C. Tso, E. R. Edelman et al., “Leukocyte recruitment and expression of chemokines following different forms of vascular injury,” Vascular Medicine, vol. 8, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, T. Imanishi, H. Ikejima et al., “Association between circulating monocyte subsets and in-stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction,” Circulation Journal, vol. 74, no. 12, pp. 2585–2591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Virmani and A. Farb, “Pathology of in-stent restenosis,” Current Opinion in Lipidology, vol. 10, no. 6, pp. 499–506, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. G. P. Amorino and R. L. Hoover, “Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production,” American Journal of Pathology, vol. 152, no. 1, pp. 199–207, 1998. View at Google Scholar · View at Scopus
  19. Y. V. Bobryshev, “Monocyte recruitment and foam cell formation in atherosclerosis,” Micron, vol. 37, no. 3, pp. 208–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Yamamoto, T. Osanai, F. Nishizaki et al., “Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α,” Heart and Vessels, vol. 27, no. 6, pp. 624–633, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Langlois, F. Chouinard, N. Flamand, C. Ferland, M. Rola-Pleszczynski, and M. Laviolette, “Crucial implication of protein kinase C (PKC)-δ, PKC-ζ, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils,” Journal of Leukocyte Biology, vol. 85, no. 4, pp. 656–663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-H. Tang and C.-C. Tsai, “CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway,” Biochemical Pharmacology, vol. 83, no. 3, pp. 335–344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Roskoski Jr., “ERK1/2 MAP kinases: structure, function, and regulation,” Pharmacological Research, vol. 66, no. 2, pp. 105–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H.-L. Hsieh, C.-Y. Wu, and C.-M. Yang, “Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-δ-dependent ERK/Elk-1 pathway in astrocytes,” Glia, vol. 56, no. 6, pp. 619–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. B. D. Choi, S. J. Jeong, G. Wang et al., “Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells,” International Journal of Molecular Medicine, vol. 28, no. 4, pp. 527–534, 2011. View at Publisher · View at Google Scholar
  26. N. Ahmad, W. Wang, R. Nair, and S. Kapila, “Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways,” Molecular and Cellular Endocrinology, vol. 363, no. 1-2, pp. 46–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. J. Hong, S. C. Choi, C. M. Ahn, J. H. Park, J. S. Kim, and D.-S. Lim, “Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients,” Heart, vol. 97, no. 17, pp. 1425–1432, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Yokoyama, T. Higuma, H. Tomita et al., “Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril,” International Journal of Cardiology, vol. 132, no. 1, pp. 114–120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Hong, W. J. Shim, J. I. Choi et al., “Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients,” American Journal of Cardiology, vol. 100, no. 11, pp. 1625–1629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Zhu, X. Zhang, H. Qiao et al., “The intrinsic PEDF is regulated by PPARγ in permanent focal cerebral ischemia of rat,” Neurochemical Research, vol. 37, no. 10, pp. 2099–2107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Nakamura, T. Inoue, T. Suzuki et al., “Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency,” Hypertension Research, vol. 31, no. 5, pp. 841–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Araújo, T. O. Souza, L. M. Moura et al., “Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model,” Journal of Clinical Periodontology, vol. 40, no. 12, pp. 1104–1111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Maejima, H. Okada, G. Haraguchi et al., “Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma,” Laboratory Investigation, vol. 91, no. 6, pp. 932–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Yokota, T. Osanai, K. Hanada et al., “Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril,” Heart and Vessels, vol. 25, no. 6, pp. 460–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. A. A. Herzlich, J. Tuo, and C.-C. Chan, “Peroxisome proliferator-activated receptor and age-related macular degeneration,” PPAR Research, vol. 2008, Article ID 389507, 11 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Müller, T. Endo, and G. Thiel, “Regulation of AP-1 activity in glucose-stimulated insulinoma cells,” Journal of Cellular Biochemistry, vol. 110, no. 6, pp. 1481–1494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. S. J. Hong, S. T. Kim, T.-J. Kim et al., “Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2655–2665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. P. S. Munk, U. M. Breland, P. Aukrust, O. Skadberg, T. Ueland, and A. I. Larsen, “Inflammatory response to percutaneous coronary intervention in stable coronary artery disease,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 1, pp. 92–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Patti, M. Chello, V. Pasceri et al., “Dexamethasone-eluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study,” Clinical Therapeutics, vol. 27, no. 9, pp. 1411–1419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. M. D. Miller and M. S. Krangel, “Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines,” Critical Reviews in Immunology, vol. 12, no. 1-2, pp. 17–46, 1992. View at Google Scholar · View at Scopus
  42. R. H. van den Berg, M. C. Faber-Krol, R. B. Sim, and M. R. Dana, “The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells,” The Journal of Immunology, vol. 161, no. 12, pp. 6924–6930, 1998. View at Google Scholar · View at Scopus
  43. S.-Y. Chuang, S.-H. Yang, and J.-H. S. Pang, “Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression,” Biochemical and Biophysical Research Communications, vol. 411, no. 2, pp. 402–408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. H. M. Dansky, C. B. Barlow, C. Lominska et al., “Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 10, pp. 1662–1667, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Setacci, G. de Donato, E. Chisci et al., “Deferred urgency carotid artery stenting in symptomatic patients: clinical lessons and biomarker patterns from a prospective registry,” European Journal of Vascular and Endovascular Surgery, vol. 35, no. 6, pp. 644–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. I.-M. Chung, J. Kim, Y. K. Pak et al., “Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries,” International Journal of Cardiology, vol. 145, no. 3, pp. 468–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Voisard, U. Munder, L. von Muller, R. Baur, and V. Hombach, “Direct inhibitory effects of Ganciclovir on ICAM-1 expression and proliferation in human coronary vascular cells (SI/MPL-ratio: >1),” Medical Science Monitor, vol. 17, no. 1, pp. PI1–PI6, 2011. View at Google Scholar
  48. C. A. Dinarello, “Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist,” International Reviews of Immunology, vol. 16, no. 5-6, pp. 457–499, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. R. R. S. Packard and P. Libby, “Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction,” Clinical Chemistry, vol. 54, no. 1, pp. 24–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Kofler, T. Nickel, and M. Weis, “Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation,” Clinical Science, vol. 108, no. 3, pp. 205–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Abe, M. Sakaguchi, S. Furukado et al., “Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 4, pp. 857–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Abe, M. Sakaguchi, S. Furukado et al., “Associations of local release of inflammatory biomarkers during carotid artery stenting with plaque echogenicity and calcification,” Cerebrovascular Diseases, vol. 30, no. 4, pp. 402–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Versaci, B. Reimers, F. Prati et al., “Prediction of cardiovascular events by inflammatory markers in patients undergoing carotid stenting,” Mayo Clinic Proceedings, vol. 87, no. 1, pp. 50–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Yamamoto, R. Morishita, N. Tomita et al., “Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease,” Circulation, vol. 102, no. 11, pp. 1308–1314, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Lutgens, M. Gijbels, M. Smook et al., “Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 6, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Hlawaty, M.-P. Jacob, L. Louedec et al., “Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 518–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. B. K. Lal, K. W. Beach, G. S. Roubin et al., “Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial,” The Lancet Neurology, vol. 11, no. 9, pp. 755–763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Faber-Elman, A. Solomon, J. A. Abraham, M. Marikovsky, and M. Schwartz, “Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation,” Journal of Clinical Investigation, vol. 97, no. 1, pp. 162–171, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Gao, C. R. Wang, F. Jiang et al., “Traumatic scratch injury in astrocytes triggers calcium influx to activate the JNK/c-Jun/AP-1 pathway and switch on GFAP expression,” Glia, vol. 61, no. 12, pp. 2063–2077, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. L. R. Gomes, L. F. Terra, R. A. M. Wailemann, L. Labriola, and M. C. Sogayar, “TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells,” BMC Cancer, vol. 12, article 26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Yao, S. Xiong, K. Klos et al., “Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-β1 in human breast cancer cells,” Oncogene, vol. 20, no. 56, pp. 8066–8074, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Mohammad, M. M. Siddiquei, M. I. Nawaz, and A. M. Abu El-Asrar, “The ERK1/2 inhibitor U0126 attenuates diabetes-induced upregulation of MMP-9 and biomarkers of inflammation in the retina,” Journal of Diabetes Research, vol. 2013, Article ID 658548, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. E.-J. Lee, S.-S. Park, W.-J. Kim, and S.-K. Moon, “IL-5-induced migration via ERK1/2-mediated MMP-9 expression by inducing activation of NF-κB in HT1376 cells,” Oncology Reports, vol. 28, no. 3, pp. 1084–1090, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Kasza, “Signal-dependent Elk-1 target genes involved in transcript processing and cell migration,” Biochimica et Biophysica Acta, vol. 1829, no. 10, pp. 1026–1033, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Kun, L. Yong, J. Bo, and S. Hai-Ming, “Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: a meta-analysis,” American Journal of Cardiovascular Drugs, vol. 11, no. 3, pp. 209–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  67. B. W. Ozanne, L. McGarry, H. J. Spence et al., “Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme,” European Journal of Cancer, vol. 36, no. 13, pp. 1640–1648, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. B. W. Ozanne, H. J. Spence, L. C. McGarry, and R. F. Hennigan, “Transcription factors control invasion: AP-1 the first among equals,” Oncogene, vol. 26, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. S.-L. Yang, S.-L. Chen, J.-Y. Wu, T.-C. Ho, and Y.-P. Tsao, “Pigment epithelium-derived factor induces interleukin-10 expression in human macrophages by induction of PPAR gamma,” Life Sciences, vol. 87, no. 1-2, pp. 26–35, 2010. View at Publisher · View at Google Scholar · View at Scopus